Elite Pharmaceuticals, Inc. (ELTP) Stock Analysis — Probabli.AI
AI-powered analysis for ELTP (Elite Pharmaceuticals, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $0.36 · Market cap: $2023.00T · AI outlook: Bullish
Elite Pharmaceuticals, Inc. operates within a highly competitive generic drug market yet presents significant growth potential through strategic distribution expansions and digital market enhancements. Despite recent legal challenges and mixed earnings, positive signals from recent revenue gains and analyst price targets far beyond current levels suggest substantial mispricing and opportunity,…
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 35% · Bear 20%
- 1-year price estimates — P10: $0 / P50: $1 / P90: $3
- Despite a generally negative short-term outlook indicated by recent legal disputes and a mixed earnings report, several positives include strong recent Q2 revenue growth, a new sales platform, and strategic…
5-Year Outlook
- Bull 50% · Neutral 30% · Bear 20%
- 5-year price estimates — P10: $0 / P50: $1 / P90: $8
SWOT Highlights
- Strength: Strong partnerships expanding distribution
- Strength: Recent pipeline expansion via drug approvals
- Risk: Legal disputes impacting outlook
- Risk: HOLD consensus from analysts
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
8 Wall Street analysts rate ELTP a HOLD with a mean price target of $5.25.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
ELTP forecast details · ELTP sentiment details · ELTP insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.